

Jan Stenvang

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/309738/jan-stenvang-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

75
papers

4,566
citations

28
h-index

67
g-index

75
ext. papers

5,529
ext. citations

6.2
avg, IF

4.98
L-index

#	Paper	IF	Citations
75	Reversal of ABCG2/BCRP-Mediated Multidrug Resistance by 5,3,5-Trihydroxy-3,6,7,4-Tetramethoxyflavone Isolated from the Australian Desert Plant Chinnock. <i>Biomolecules</i> , 2021 , 11,	5.9	2
74	Molecular Profiling of Docetaxel-Resistant Prostate Cancer Cells Identifies Multiple Mechanisms of Therapeutic Resistance. <i>Cancers</i> , 2021 , 13,	6.6	2
73	New use for old drugs: Epirubicin in colorectal cancer. <i>Acta Oncologica</i> , 2021 , 60, 954-956	3.2	1
72	A Comprehensive RNA Study to Identify circRNA and miRNA Biomarkers for Docetaxel Resistance in Breast Cancer. <i>Frontiers in Oncology</i> , 2021 , 11, 669270	5.3	4
71	Synthesis of thiazole linked chalcones and their pyrimidine analogues as anticancer agents. <i>Synthetic Communications</i> , 2021 , 51, 1406-1416	1.7	1
70	Pharmacodynamic modelling reveals synergistic interaction between docetaxel and SCO-101 in a docetaxel-resistant triple negative breast cancer cell line. <i>European Journal of Pharmaceutical Sciences</i> , 2020 , 148, 105315	5.1	5
69	The Pyrazolo[3,4-d]pyrimidine Derivative, SCO-201, Reverses Multidrug Resistance Mediated by ABCG2/BCRP. <i>Cells</i> , 2020 , 9,	7.9	8
68	Four phase 1 trials to evaluate the safety and pharmacokinetic profile of single and repeated dosing of SCO-101 in adult male and female volunteers. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2020 , 127, 329-337	3.1	3
67	Characterization of resistance to a recombinant hexameric Fas-ligand (APO010) in human cancer cell lines. <i>Experimental Hematology</i> , 2020 , 87, 33-41.e4	3.1	1
66	An Explorative Analysis of mRNA Expression as a Biomarker Test for FOLFIRI Treatment in Stage III Colon Cancer Patients: Results from Retrospective Analyses of the PETACC-3 Trial. <i>Cancers</i> , 2020 , 12,	6.6	3
65	ABCG2 Protein Levels and Association to Response to First-Line Irinotecan-Based Therapy for Patients with Metastatic Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	4
64	Metallopeptidase inhibitor 1 (TIMP-1) promotes receptor tyrosine kinase c-Kit signaling in colorectal cancer. <i>Molecular Oncology</i> , 2019 , 13, 2646-2662	7.9	5
63	Two open-label, single arm, non-randomized phase II studies of irinotecan for the treatment of metastatic breast cancer in patients with increased copy number of the topoisomerase I gene. <i>BMC Cancer</i> , 2019 , 19, 573	4.8	4
62	Gel-Based Proteomics of Clinical Samples Identifies Potential Serological Biomarkers for Early Detection of Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2019 , 20,	6.3	6
61	Therapeutic application of multipotent stem cells. <i>Journal of Cellular Physiology</i> , 2018 , 233, 2815-2823	7	70
60	State of the art in microRNA as diagnostic and therapeutic biomarkers in chronic lymphocytic leukemia. <i>Journal of Cellular Physiology</i> , 2018 , 233, 888-900	7	67
59	lncRNA profile study reveals the mRNAs and lncRNAs associated with docetaxel resistance in breast cancer cells. <i>Scientific Reports</i> , 2018 , 8, 17970	4.9	34

58	Metagenomic analysis of faecal microbiome as a tool towards targeted non-invasive biomarkers for colorectal cancer. <i>Gut</i> , 2017 , 66, 70-78	19.2	488
57	Topoisomerase I copy number alterations as biomarker for irinotecan efficacy in metastatic colorectal cancer. <i>BMC Cancer</i> , 2017 , 17, 48	4.8	11
56	BMP-2 induces EMT and breast cancer stemness through Rb and CD44. <i>Cell Death Discovery</i> , 2017 , 3, 17039	6.9	37
55	Comprehensive genomic analysis of Oesophageal Squamous Cell Carcinoma reveals clinical relevance. <i>Scientific Reports</i> , 2017 , 7, 15324	4.9	25
54	Implications of ABCG2 Expression on Irinotecan Treatment of Colorectal Cancer Patients: A Review. <i>International Journal of Molecular Sciences</i> , 2017 , 18,	6.3	28
53	ABCG2 and TOP1 mRNA expression as predictive biomarkers for adjuvant FOLFIRI treatment in stage III colon cancer patients: Results from the PETAAC-3 prospective randomized clinical trial.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 591-591	2.2	3
52	Screening of 129 FDA approved anti-cancer drugs in colorectal cancer cell lines resistant to oxaliplatin or irinotecan (SN38).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 642-642	2.2	1
51	Drug Resistance in Colorectal Cancer Cell Lines is Partially Associated with Aneuploidy Status in Light of Profiling Gene Expression. <i>Journal of Proteome Research</i> , 2016 , 15, 4047-4059	5.6	13
50	The stepwise evolution of the exome during acquisition of docetaxel resistance in breast cancer cells. <i>BMC Genomics</i> , 2016 , 17, 442	4.5	21
49	Repurposing Cationic Amphiphilic Antihistamines for Cancer Treatment. <i>EBioMedicine</i> , 2016 , 9, 130-139	8.8	57
48	The volume regulated anion channel inhibitor NS3728 to enhance the cytotoxic effects of SN-38 in human colorectal cancer cells grown in vitro.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e23170-e23170	2.2	1
47	Integrative analysis of miRNA and gene expression reveals regulatory networks in tamoxifen-resistant breast cancer. <i>Oncotarget</i> , 2016 , 7, 57239-57253	3.3	24
46	Antibody validation and scoring guidelines for ABCG2 immunohistochemical staining in formalin-fixed paraffin-embedded colon cancer tissue. <i>Scientific Reports</i> , 2016 , 6, 26997	4.9	4
45	miRNA profiling of circulating EpCAM(+) extracellular vesicles: promising biomarkers of colorectal cancer. <i>Journal of Extracellular Vesicles</i> , 2016 , 5, 31488	16.4	63
44	Characterization of DNA topoisomerase I in three SN-38 resistant human colon cancer cell lines reveals a new pair of resistance-associated mutations. <i>Journal of Experimental and Clinical Cancer Research</i> , 2016 , 35, 56	12.8	18
43	Molecular characterization of irinotecan (SN-38) resistant human breast cancer cell lines. <i>BMC Cancer</i> , 2016 , 16, 34	4.8	28
42	A phase II study of Epirubicin in oxaliplatin-resistant patients with metastatic colorectal cancer and TOP2A gene amplification. <i>BMC Cancer</i> , 2016 , 16, 91	4.8	22
41	Topoisomerase-1 and -2A gene copy numbers are elevated in mismatch repair-proficient colorectal cancers. <i>Molecular Oncology</i> , 2015 , 9, 1207-17	7.9	17

40	Establishment and characterization of models of chemotherapy resistance in colorectal cancer: Towards a predictive signature of chemoresistance. <i>Molecular Oncology</i> , 2015 , 9, 1169-85	7.9	57
39	Topoisomerase-1 gene copy aberrations are frequent in patients with breast cancer. <i>International Journal of Cancer</i> , 2015 , 137, 2000-6	7.5	12
38	A phase II study of weekly irinotecan in patients with locally advanced or metastatic HER2- negative breast cancer and increased copy numbers of the topoisomerase 1 (TOP1) gene: a study protocol. <i>BMC Cancer</i> , 2015 , 15, 78	4.8	8
37	The glutamate transport inhibitor DL-Threo-β-Benzyloxyaspartic acid (DL-TBOA) differentially affects SN38- and oxaliplatin-induced death of drug-resistant colorectal cancer cells. <i>BMC Cancer</i> , 2015 , 15, 411	4.8	12
36	Drug transporters in breast cancer: response to anthracyclines and taxanes. <i>Expert Review of Anticancer Therapy</i> , 2015 , 15, 1075-92	3.5	5
35	The potential role of Alu Y in the development of resistance to SN38 (Irinotecan) or oxaliplatin in colorectal cancer. <i>BMC Genomics</i> , 2015 , 16, 404	4.5	11
34	Acquisition of docetaxel resistance in breast cancer cells reveals upregulation of ABCB1 expression as a key mediator of resistance accompanied by discrete upregulation of other specific genes and pathways. <i>Tumor Biology</i> , 2015 , 36, 4327-38	2.9	28
33	TOP1 gene copy numbers are increased in cancers of the bile duct and pancreas. <i>Scandinavian Journal of Gastroenterology</i> , 2015 , 50, 485-94	2.4	9
32	Purification and characterization of bioactive his6-tagged recombinant human tissue inhibitor of metalloproteinases-1 (TIMP-1) protein expressed at high yields in mammalian cells. <i>Protein Expression and Purification</i> , 2014 , 101, 157-64	2	6
31	No effect of ablation of surfactant protein-D on acute cerebral infarction in mice. <i>Journal of Neuroinflammation</i> , 2014 , 11, 123	10.1	16
30	Measuring ERCC1 protein expression in cancer specimens: validation of a novel antibody. <i>Scientific Reports</i> , 2014 , 4, 4313	4.9	15
29	Progesterone receptor isoform A may regulate the effects of neoadjuvant aglepristone in canine mammary carcinoma. <i>BMC Veterinary Research</i> , 2014 , 10, 296	2.7	5
28	Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. <i>PLoS ONE</i> , 2014 , 9, e95192	3.7	661
27	TIMP1 overexpression mediates resistance of MCF-7 human breast cancer cells to fulvestrant and down-regulates progesterone receptor expression. <i>Tumor Biology</i> , 2013 , 34, 3839-51	2.9	14
26	TIMP-1 overexpression does not affect sensitivity to HER2-targeting drugs in the HER2-gene-amplified SK-BR-3 human breast cancer cell line. <i>Tumor Biology</i> , 2013 , 34, 1161-70	2.9	3
25	Proximity probing assays for simultaneous visualization of protein complexes in situ. <i>Expert Review of Proteomics</i> , 2013 , 10, 219-21	4.2	3
24	Plasma levels of the MMP-9:TIMP-1 complex as prognostic biomarker in breast cancer: a retrospective study. <i>BMC Cancer</i> , 2013 , 13, 598	4.8	18
23	TIMP-1 increases expression and phosphorylation of proteins associated with drug resistance in breast cancer cells. <i>Journal of Proteome Research</i> , 2013 , 12, 4136-51	5.6	26

22	High expression of microRNA-625-3p is associated with poor response to first-line oxaliplatin based treatment of metastatic colorectal cancer. <i>Molecular Oncology</i> , 2013 , 7, 637-46	7.9	71
21	A systematic review on topoisomerase 1 inhibition in the treatment of metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2013 , 138, 347-58	4.4	48
20	Detection of serological biomarkers by proximity extension assay for detection of colorectal neoplasias in symptomatic individuals. <i>Journal of Translational Medicine</i> , 2013 , 11, 253	8.5	31
19	Integrative analyses of gene expression and DNA methylation profiles in breast cancer cell line models of tamoxifen-resistance indicate a potential role of cells with stem-like properties. <i>Breast Cancer Research</i> , 2013 , 15, R119	8.3	37
18	Biomarker-guided repurposing of chemotherapeutic drugs for cancer therapy: a novel strategy in drug development. <i>Frontiers in Oncology</i> , 2013 , 3, 313	5.3	31
17	Colorectal cancer cell lines made resistant to SN38-and Oxaliplatin: Roles of altered ion transporter function in resistance?. <i>FASEB Journal</i> , 2013 , 27, lb452	0.9	
16	Inhibition of microRNA function by anti-miR oligonucleotides. <i>Silence: A Journal of RNA Regulation</i> , 2012 , 3, 1		372
15	The therapeutic potential of microRNAs in cancer. <i>Cancer Journal (Sudbury, Mass)</i> , 2012 , 18, 275-84	2.2	84
14	Silencing of microRNA families by seed-targeting tiny LNAs. <i>Nature Genetics</i> , 2011 , 43, 371-8	36.3	521
13	Multiplexed homogeneous proximity ligation assays for high-throughput protein biomarker research in serological material. <i>Molecular and Cellular Proteomics</i> , 2011 , 10, M110.004978	7.6	62
12	MicroRNA-138 regulates osteogenic differentiation of human stromal (mesenchymal) stem cells in vivo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011 , 108, 6139-44	11.5	386
11	MicroRNAs, epigenetics and disease. <i>Essays in Biochemistry</i> , 2010 , 48, 165-85	7.6	28
10	MiR-155 is overexpressed in patients with atopic dermatitis and modulates T-cell proliferative responses by targeting cytotoxic T lymphocyte-associated antigen 4. <i>Journal of Allergy and Clinical Immunology</i> , 2010 , 126, 581-9.e1-20	11.5	208
9	Silencing of microRNA-155 in mice during acute inflammatory response leads to derepression of c/ebp Beta and down-regulation of G-CSF. <i>Nucleic Acids Research</i> , 2009 , 37, 5784-92	20.1	160
8	Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant. <i>Breast Cancer Research and Treatment</i> , 2009 , 114, 263-75	4.4	111
7	The utility of LNA in microRNA-based cancer diagnostics and therapeutics. <i>Seminars in Cancer Biology</i> , 2008 , 18, 89-102	12.7	157
6	MicroRNAs as targets for antisense-based therapeutics. <i>Expert Opinion on Biological Therapy</i> , 2008 , 8, 59-81	5.4	90
5	Targeting of microRNAs for therapeutics. <i>Biochemical Society Transactions</i> , 2008 , 36, 1197-200	5.1	46

4	Protein Kinase C alpha is a marker for antiestrogen resistance and is involved in the growth of tamoxifen resistant human breast cancer cells. <i>Breast Cancer Research and Treatment</i> , 2007 , 104, 165-79 ^{4.4}	30
3	A novel dual-target steroid sulfatase inhibitor and antiestrogen: SR 16157, a promising agent for the therapy of breast cancer. <i>Breast Cancer Research and Treatment</i> , 2007 , 106, 191-203	4.4 39
2	Breast cancer cells with acquired antiestrogen resistance are sensitized to cisplatin-induced cell death. <i>Molecular Cancer Therapeutics</i> , 2007 , 6, 1869-76	6.1 23
1	Induction of cell death in antiestrogen resistant human breast cancer cells by the protein kinase CK2 inhibitor DMAT. <i>Cancer Letters</i> , 2007 , 256, 229-37	9.9 41